Drug Trial Radar · NCT03161431
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
77
Planned (sponsor's estimate)
Start
Jun 12, 2019
Primary completion
Jul 31, 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Syntrix Biosystems, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Massachusetts General Hospital; National Cancer Institute (NCI); Dana-Farber Cancer Institute; Mayo Clinic; University of Rochester; M.D. Anderson Cancer Center; University of Miami
- First posted
- May 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer has been shown to be able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective treatment of melanoma. It is thought that SX-682 will block MDSCs from going to the cancer, and thus will allow a patient's own immune system to attack the cancer. The first participants enrolled in the study will receive for 21 days SX-682 as monotherapy. After 21 days participants will receive pembrolizumab therapy (an approved immunotherapy for melanoma) in combination with SX-682 for up to approximately 2 years. Once the safe dose level of SX-682 in combination with pembrolizumab is determined, the remaining participants will be enrolled at the highest safe dose level of SX-682, in combination with pembrolizumab. These participants will receive the combination therapy and be evaluated in the study for approximately 2 years.
Conditions
- Melanoma Stage III
- Melanoma Stage IV
Interventions
SX-682Drug
SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
PembrolizumabBiological
Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
Primary outcomes
What the sponsor says the trial is designed to measure.
- SX-682 Maximum Tolerated Dose (MTD) during Monotherapy StageTime frame: Up to 21 Days in 21 day Cycle 1 of Monotherapy Stage.
- SX-682 Maximum Tolerated Dose during Combination Therapy StageTime frame: Up to 42 Days in 42 day Cycle 1 of Combination Therapy Stage.
- The observed tumor response rateTime frame: Days 38-42 of each 42 day Combination Stage cycle (Cycles 1-17)
- The observed tumor response durationTime frame: Days 38-42 of each 42 day Combination Stage cycle (Cycles 1-17)
- Progression free survivalTime frame: Days 38-42 of each 42 day Combination Stage cycle (Cycles 1-17)
- Overall survivalTime frame: Combination Stage cycle (Cycles 1-17) and the 90 day follow-up period after the last SX-682 dose.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Miami
Miami, Florida
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Wilmot Cancer Institute - University of Rochester
Rochester, New York
MD Anderson
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.